샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794531

세계의 강박장애 치료제 시장

Obsessive-Compulsive Disorder Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 282 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 강박장애 치료제 시장은 2030년까지 15억 달러에 도달

2024년에 11억 달러로 추정되는 세계의 강박장애 치료제 시장은 2024-2030년의 분석 기간에 CAGR 5.3%로 성장하며, 2030년에는 15억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 SSRI는 CAGR 6.2%를 기록하며, 분석 기간 종료시에는 9억 7,390만 달러에 달할 것으로 예측됩니다. TCA 부문의 성장률은 분석 기간 중 CAGR 3.4%로 추정됩니다.

미국 시장은 2억 9,230만 달러로 추정, 중국은 CAGR 8.6%로 성장 예측

미국의 강박장애 치료제 시장은 2024년에 2억 9,230만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 8.6%로 추이하며, 2030년에는 2억 9,500만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.5%와 5.3%로 예측됩니다. 유럽에서는 독일이 CAGR 3.4%로 성장할 것으로 예측됩니다.

세계의 강박장애 치료제 시장 - 주요 동향과 촉진요인 정리

강박장애의 치료 요구는 의약품 개발에 어떤 영향을 미치고 있는가?

강박장애(OCD)는 일상생활에 지장을 초래하는 강박관념이나 강박행동을 반복하는 만성적인 정신질환입니다. OCD를 치료하기 위해서는 약리학적, 심리적 개입을 병행해야 합니다. 약물요법 중 선택적 세로토닌 재흡수 억제제(SSRI)가 1차 선택약물이며, 플루옥세틴, 플루복사민, 셀트랄린 등이 널리 처방되고 있습니다. 이 약물들은 강박증에 중요한 역할을 하는 것으로 여겨지는 세로토닌 수치를 조절하는 데 도움이 됩니다.

SSRI는 그 효과에도 불구하고 모든 환자에게 보편적으로 도움이 되는 것은 아니며, 많은 환자에서 부분적인 반응이나 치료 저항성을 보이는 경우가 있습니다. 이러한 한계로 인해, 특히 SSRI 단독요법이 불충분한 경우 리스페리돈이나 아리피프라졸과 같은 항정신병제물을 사용하는 증강요법에 대한 관심이 높아지고 있습니다. 보다 표적화되고 즉각적인 치료법의 필요성으로 인해 글루타메이트 및 기타 신경 전달 경로를 조절하는 새로운 화합물에 대한 제약 연구가 계속되고 있습니다.

선택의 폭을 넓히는 데 있으며, 혁신과 연구는 어떤 역할을 할 수 있는가?

최근 신경약리학의 발전은 OCD 치료제 개발에 새로운 길을 열어주고 있습니다. 연구자들은 글루타메이트 전달 및 염증과 관련된 기전을 표적으로 하는 약물을 탐색하고 있으며, 기존의 세로토닌을 중심으로 한 치료법에 대한 대안을 제시하고 있습니다. 연구 중인 약물에는 NMDA 수용체 조절제, 도파민과 노르에피네프린에 작용하는 재흡수 억제제 등이 있으며, 현재 치료법에 반응하지 않는 환자들을 구제할 수 있는 가능성이 있습니다.

케타민이나 기분 안정제와 같은 특정 약물의 적응증 외 사용도 치료 저항성 증상을 감소시킬 수 있는 것으로 연구되고 있습니다. 또한 환자의 생물학적 프로파일에 따라 보다 효과적으로 치료법을 적용하기 위한 약리유전학적 접근법도 연구되고 있습니다. 이러한 기술 혁신은 OCD 치료를 개인화하고 정신과 약물 치료에서 일반적으로 직면하는 시행착오의 부담을 줄이기 위한 광범위한 노력을 반영합니다.

헬스케어 시스템과 접근 패턴은 어떻게 시장 동향을 형성하고 있는가?

OCD 치료제에 대한 접근성은 정신과 의료 서비스의 향상과 1차 의료 서비스 프로바이더의 인식 개선으로 확대되고 있습니다. 특히 청소년과 청년층에서 OCD 진단 비율이 증가함에 따라 적시에 약리학적 개입에 대한 수요가 증가하고 있습니다. 신흥 경제국에서는 국가 의료제도와 정신과 치료에 대한 보험 적용으로 인해 보다 폭넓은 치료를 받을 수 있게 되었습니다. 그러나 중저소득 국가에서는 정신과 인프라가 제한적이고, 약품의 접근이 어려워 여전히 격차가 남아있습니다.

원격의료와 디지털 정신건강 플랫폼도 특히 의료 혜택이 부족한 지역에서 환자의 정신과 의료 접근성을 개선하고 있습니다. 이러한 플랫폼은 복약 관리와 복약 순응도를 지원하여 환자가 치료의 연속성을 유지할 수 있도록 돕습니다. 제약사들은 조기 개입, 부작용 관리, 복약 순응도의 중요성에 대한 교육을 개선하기 위해 정신건강 서비스 프로바이더와의 협력을 강화하고 있습니다.

강박증 치료제 시장의 성장은 몇 가지 요인에 의해 이루어집니다.

진단율 증가, 정신건강에 대한 일반 대중의 인식 증가, 보험 적용 범위 확대 등이 약리학적 개입에 대한 수요 증가에 기여하고 있습니다. 원격 정신의료와 디지털 헬스 플랫폼의 확대로 약물과 치료 지원에 대한 적시 접근이 쉬워지고 있습니다. 신경화학 연구의 혁신은 SSRI를 넘어서는 신약 후보물질의 개발을 가능하게 하고, 약리유전학 연구는 보다 개인화된 치료법의 토대를 마련하고 있습니다. 또한 연령대와 문화적 배경을 넘어 정신과 의료에 대한 수용도가 높아지고 있는 것도 전 세계 의료 시스템에서 OCD 치료제에 대한 지속적인 수요 증가를 지원하고 있습니다.

부문

약제 클래스별(SSRI, TCA, 기타 약제 클래스); 요법(인지 행동 요법, 증강 요법, 혐오 요법, 계통적 탈감작료법, 기타 요법)

조사 대상 기업의 예

  • AbbVie Inc.
  • Allergan plc
  • Amorsa Therapeutics Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Biohaven Pharmaceuticals Inc.
  • Cannabis Science Inc.
  • Ceruvia Lifesciences LLC
  • Eli Lilly and Company
  • Lundbeck A/S
  • Octapharma AG
  • Omeros Corporation
  • PharmaTher Holdings Ltd
  • Pfizer Inc.
  • Phytecs
  • Rugen Therapeutics R&D Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Wisdom Therapeutics(formerly Evecxia)

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Obsessive-Compulsive Disorder Drugs Market to Reach US$1.5 Billion by 2030

The global market for Obsessive-Compulsive Disorder Drugs estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. SSRI, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$973.9 Million by the end of the analysis period. Growth in the TCA segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$292.3 Million While China is Forecast to Grow at 8.6% CAGR

The Obsessive-Compulsive Disorder Drugs market in the U.S. is estimated at US$292.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$295.0 Million by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Obsessive-Compulsive Disorder Drugs Market - Key Trends & Drivers Summarized

How Are Treatment Needs for OCD Influencing Drug Development?

Obsessive-compulsive disorder (OCD) is a chronic mental health condition characterized by recurring, intrusive thoughts and compulsive behaviors that interfere with daily functioning. Managing OCD often requires a combination of pharmacological and psychological interventions. Among pharmaceutical options, selective serotonin reuptake inhibitors (SSRIs) remain the first-line treatment, with fluoxetine, fluvoxamine, and sertraline being widely prescribed. These drugs help regulate serotonin levels, which are believed to play a key role in obsessive-compulsive symptoms.

Despite their effectiveness, SSRIs are not universally beneficial for all patients, and many experience partial response or treatment resistance. This limitation has led to growing interest in augmentation therapies, such as the use of antipsychotic medications like risperidone and aripiprazole, especially in cases where monotherapy with SSRIs proves inadequate. The need for more targeted, faster-acting treatments continues to drive pharmaceutical research toward novel compounds that modulate glutamate or other neurotransmitter pathways.

What Role Do Innovation and Research Play in Expanding Options?

Recent advancements in neuropharmacology are opening new avenues for OCD drug development. Researchers are exploring agents that target glutamatergic transmission and inflammation-related mechanisms, offering alternatives to traditional serotonin-focused therapies. Drugs under investigation include NMDA receptor modulators and reuptake inhibitors affecting dopamine and norepinephrine, which may provide relief for patients who do not respond well to current options.

Off-label use of certain medications, including ketamine and mood stabilizers, is also being studied for their potential to reduce treatment-resistant symptoms. Moreover, pharmacogenetic approaches are being explored to match patients with therapies more effectively based on their biological profile. These innovations reflect a broader effort to personalize OCD treatment and reduce the trial-and-error burden commonly faced in psychiatric drug therapy.

How Are Healthcare Systems and Access Patterns Shaping Market Trends?

Access to OCD medications is expanding through improved mental health services and better awareness among primary care providers. As OCD diagnosis rates increase, particularly among adolescents and young adults, demand for timely pharmacological intervention is growing. National healthcare programs and insurance coverage for psychiatric treatments are supporting wider access in developed economies. In low- and middle-income countries, however, gaps remain due to limited psychiatric infrastructure and inconsistent drug availability.

Telemedicine and digital mental health platforms are also improving patient access to psychiatric care, especially in underserved regions. These platforms support medication management and compliance, helping patients maintain continuity in treatment. Pharmaceutical companies are increasingly collaborating with mental health providers to improve education around early intervention, side effect management, and the importance of medication adherence.

Growth in the obsessive-compulsive disorder drugs market is driven by several factors.

Rising diagnosis rates, growing public awareness of mental health, and broader insurance coverage are contributing to higher demand for pharmacological interventions. Expansion of telepsychiatry and digital health platforms is facilitating timely access to medications and treatment support. Innovation in neurochemical research is enabling development of novel drug candidates beyond SSRIs, while pharmacogenetic exploration is laying the groundwork for more individualized therapies. Increasing acceptance of psychiatric care across age groups and cultural contexts is also supporting sustained growth in demand for OCD medications across global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Obsessive-Compulsive Disorder Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (SSRI, TCA, Other Drug Classes); Therapy (Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization, Other Therapies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AbbVie Inc.
  • Allergan plc
  • Amorsa Therapeutics Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Biohaven Pharmaceuticals Inc.
  • Cannabis Science Inc.
  • Ceruvia Lifesciences LLC
  • Eli Lilly and Company
  • Lundbeck A/S
  • Octapharma AG
  • Omeros Corporation
  • PharmaTher Holdings Ltd
  • Pfizer Inc.
  • Phytecs
  • Rugen Therapeutics R&D Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Wisdom Therapeutics (formerly Evecxia)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Obsessive-Compulsive Disorder Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising OCD Diagnosis Rates Globally Spur Demand for Pharmaceutical Interventions
    • Increased Mental Health Awareness Strengthens Business Case for OCD Drug Development
    • Expansion of Telepsychiatry and Digital Health Platforms Drives Access to OCD Treatment Options
    • Growing Acceptance of Psychiatric Medications Reduces Stigma and Propels OCD Drug Adoption
    • Advancements in Neurobiological Research Accelerate Discovery of Novel OCD Drug Targets
    • Rising Comorbidity of OCD with Depression and Anxiety Expands Addressable Treatment Population
    • Strong Pipeline of Novel Therapies Drives Investor Interest and Market Growth Potential
    • Introduction of Rapid-Acting Therapies Throws the Spotlight on Next-Generation OCD Treatments
    • Growing Preference for SSRIs and SNRIs Sustains Demand in First-Line OCD Therapy Segment
    • Emergence of Glutamate Modulators and NMDA Antagonists Creates New Therapeutic Avenues
    • Increasing Off-Label Use of Antipsychotics Enhances Market Opportunity in Treatment-Resistant OCD
    • Focus on Personalized Psychiatry Generates Demand for Pharmacogenomic-Guided OCD Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Obsessive-Compulsive Disorder Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Obsessive-Compulsive Disorder Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for SSRI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for SSRI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for SSRI by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for TCA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for TCA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for TCA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cognitive Behavioral Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cognitive Behavioral Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Cognitive Behavioral Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Augmentation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Augmentation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Augmentation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Aversion Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Aversion Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Aversion Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Systematic Desensitization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Systematic Desensitization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Systematic Desensitization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • JAPAN
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • CHINA
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • EUROPE
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Obsessive-Compulsive Disorder Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • FRANCE
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • GERMANY
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Obsessive-Compulsive Disorder Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • INDIA
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Obsessive-Compulsive Disorder Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Obsessive-Compulsive Disorder Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • AFRICA
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제